依达拉奉治疗急性脑梗死的临床疗效观察  

作　　者：李皓亮[1] 

机构地区：[1]郑州市第七人民医院,450006

出　　处：《中国现代药物应用》2010年第20期13-14,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨依达拉奉注射液(必存注射液)对治疗急性脑梗死的疗效。方法选择发病72h内的急性脑梗死患者158例,随机分为必存组(79例)和对照组(79例),分别于治疗前和治疗后2周进行临床疗效和神经缺失分数减少程度评定。结果治疗2周后,必存组总有效率为92.41%;对照组总有效率为77.22%,两组相比差异具有统计学意义(P<0.01)。结论依达拉奉对急性脑梗死患者有较好的疗效,值得推广应用。Objective To explore the effects of edaravone on acute cerebral infarction（ACI） patients.Methods 158 ACI patients who had an onset with in 72 hours were allocated to edaravone group（79 cases） and the control group（79 cases）.The clinical effect and the degree of nerve defscit cores were used in the two groups befour treatment and after.Results The effective point were 92.41% with edaravone group after 2 weeks,and the effective point were 77.22% with the control group,There was a significant difference in the two groups（P 0.01）.Conclusion Edaravone has a higher curative effect with ACI,it is worthy to be recommended for clinical application.

关 键 词：必存 急性脑梗死 临床疗效 

分 类 号：R743.3[医药卫生—神经病学与精神病学]